Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Osmotica Pharmaceuticals stock | $4.36

Own Osmotica Pharmaceuticals stock in just a few minutes.

Fact checked

Osmotica Pharmaceuticals plc is a biotechnology business based in the US. Osmotica Pharmaceuticals shares (OSMT) are listed on the NASDAQ and all prices are listed in US Dollars. Osmotica Pharmaceuticals employs 379 staff and has a trailing 12-month revenue of around USD$203.3 million.

How to buy shares in Osmotica Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Osmotica Pharmaceuticals. Find the stock by name or ticker symbol: OSMT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Osmotica Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$4.36, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Osmotica Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Osmotica Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Osmotica Pharmaceuticals share price

Use our graph to track the performance of OSMT stocks over time.

Osmotica Pharmaceuticals shares at a glance

Information last updated 2021-01-19.
Latest market closeUSD$4.36
52-week rangeUSD$2.81 - USD$7.38
50-day moving average USD$5.2679
200-day moving average USD$5.6526
Wall St. target priceUSD$8.4
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.824

Buy Osmotica Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Osmotica Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Osmotica Pharmaceuticals price performance over time

Historical closes compared with the close of $4.36 from 2021-01-11

1 week (2021-01-09) N/A
1 month (2020-12-16) -25.72%
3 months (2020-10-16) -27.09%
6 months (2020-07-16) -26.97%
1 year (2020-01-16) -22.28%
2 years (2019-01-16) -49.54%
3 years (2018-01-16) N/A
5 years (2016-01-16) N/A

Is Osmotica Pharmaceuticals under- or over-valued?

Valuing Osmotica Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Osmotica Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Osmotica Pharmaceuticals's EBITDA

Osmotica Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$32.7 million.

The EBITDA is a measure of a Osmotica Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Osmotica Pharmaceuticals financials

Revenue TTM USD$203.3 million
Operating margin TTM 8.37%
Gross profit TTM USD$128.4 million
Return on assets TTM 2.31%
Return on equity TTM -35.13%
Profit margin -25.27%
Book value $2.388
Market capitalisation USD$272.2 million

TTM: trailing 12 months

Shorting Osmotica Pharmaceuticals shares

There are currently 1.2 million Osmotica Pharmaceuticals shares held short by investors – that's known as Osmotica Pharmaceuticals's "short interest". This figure is 4.5% up from 1.2 million last month.

There are a few different ways that this level of interest in shorting Osmotica Pharmaceuticals shares can be evaluated.

Osmotica Pharmaceuticals's "short interest ratio" (SIR)

Osmotica Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Osmotica Pharmaceuticals shares currently shorted divided by the average quantity of Osmotica Pharmaceuticals shares traded daily (recently around 667333.69565217). Osmotica Pharmaceuticals's SIR currently stands at 1.84. In other words for every 100,000 Osmotica Pharmaceuticals shares traded daily on the market, roughly 1840 shares are currently held short.

However Osmotica Pharmaceuticals's short interest can also be evaluated against the total number of Osmotica Pharmaceuticals shares, or, against the total number of tradable Osmotica Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Osmotica Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Osmotica Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0791% of the tradable shares (for every 100,000 tradable Osmotica Pharmaceuticals shares, roughly 79 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Osmotica Pharmaceuticals.

Find out more about how you can short Osmotica Pharmaceuticals stock.

Osmotica Pharmaceuticals share dividends

We're not expecting Osmotica Pharmaceuticals to pay a dividend over the next 12 months.

Osmotica Pharmaceuticals share price volatility

Over the last 12 months, Osmotica Pharmaceuticals's shares have ranged in value from as little as $2.81 up to $7.38. A popular way to gauge a stock's volatility is its "beta".

OSMT.US volatility(beta: 2.41)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Osmotica Pharmaceuticals's is 2.4126. This would suggest that Osmotica Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Osmotica Pharmaceuticals overview

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; ConZip, a tramadol hydrochloride extended-release capsule to treat pain; and Arbaclofen tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site